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Abstract
Background: Double-hit lymphomas (DHL) are rare high-grade neoplasms characterized by two translocations:
one involving the gene MYC and another involving genes BCL2 or BCL6, whose diagnosis depends on cytogenetic
examination. This research studied DHL and morphological and/or immunophenotypic factors associated with the
detection of these translocations in a group of high-grade non-Hodgkin lymphoma cases.
Method: Clinical and morphological reviews of 120 cases diagnosed with diffuse large B-cell lymphoma and Burkitt
lymphoma were conducted. Immunohistochemistry (CD20, CD79a, PAX5, CD10, Bcl6, Bcl2, MUM1, TDT and Myc)
and fluorescence in situ hybridization for detection of MYC, BCL2 and BCL6 gene translocations were performed in
a tissue microarray platform.
Results: Three cases of DHL were detected: two with translocations of MYC and BCL2 and one with translocations of
MYC and BCL6, all leading to death in less than six months. Among 90 cytogenetically evaluable biopsies, associations
were determined between immunohistochemistry and fluorescence in situ hybridization for MYC (p = 0.036) and BCL2
(p = 0.001). However, these showed only regular agreement, indicated by Kappa values of 0.23 [0.0;0.49] and 0.35 [0.13;
0.56], respectively. “Starry sky” morphology was strongly associated with MYC positivity (p = 0.01). The detection of three
cases of DHL, all resulting in death, confirms the rarity and aggressiveness of this neoplasm.
Conclusions: The “starry sky” morphological pattern and immunohistochemical expression of Myc and Bcl2 represent
possible selection factors for additional cytogenetic diagnostic testing.
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Background
Double-hit lymphomas (DHL) are aggressive neo-
plasms presenting translocation phenomenon involv-
ing the MYC gene combined with another event
involving translocation of the BCL2 or BCL6 gene
[1–6]. The combination of MYC translocation with
translocations of BCL2 and BCL6 can also occur, de-
fining the triple-hit lymphomas (THL) [1, 4, 7–9]. A
diagnosis of DHL is only determined following the
results of a cytogenetic test, such as fluorescence in
situ hybridization (FISH) [10–12]. It represents
approximately 15% of the provisional entity called B-
cell lymphoma unclassifiable, with features intermedi-
ate between diffuse large B-cell lymphoma and
Burkitt lymphoma (B-CLU/DLBCL/LB), Classification of
Tumors of Haematopoietic and Lymphoid Tissues of the
World Health Organization (WHO) in 2008 [1–4].
In 2016, Swerdlow et al. [13] published a proposal
of revision in the WHO classification of 2008. This
group of authors recognized DHL and THL as clin-
ical and pathological categories, designated high-
grade B-cell lymphomas (HGBL) with MYC and
BCL2 and/or BCL6 rearrangements. Cases with mor-
phological aspects of HGBL without MYC and BCL2
and/or BCL6 rearrangements were placed in the
HGBL, NOS. However, there is not a specific guide-
line to select which cases should have FISH studies
[13]. The morphological and/or immunophenotypic
parameters do not seem to effectively predict the de-
tection of cytogenetic translocations involving MYC,
BCL2 and BCL6 [4, 14]. Molecular cytogenetics, like
FISH, is not a readily available technique, mainly due
to its high costs. Thus, determining which group of
patients must have their biopsies submitted for this
kind of test is a subject of controversy [4, 14, 15].
Despite the difficulties in interpreting the immuno-
histochemical profiles of Myc, Bcl2 and Bcl6, several
studies have been published on how this technique
can be used as a method of screening for molecular
research, since it is being incorporated into the clin-
ical routine as this cytogenetic information becomes
increasingly relevant in therapeutic practice and
prognosis [16, 17].
This study identified cases of DHL in a series of
high-grade non-Hodgkin lymphomas in Brazil,
characterizing them according to their clinical,
morphological, immunophenotypic and molecular
features. In addition, the associations between the
expression of Myc, Bcl2 and Bcl6 proteins assessed
by immunohistochemistry and the detection of trans-
locations involving these genes were investigated in
order to contribute to the discussions about how to
select the cases of lymphoma for further molecular
studies.
Method
Patients and study design
The authors selected 120 cases of patients with a patho-
logical diagnosis of DLBCL or BL from two reference
hospitals. Among the 120 cases selected following a
review of pathology reports, 100 patients were diagnosed
with DLBCL and 20 patients were diagnosed with LB.
Patient records were reviewed from January 1998 to
December 2013 at HC-FMB-UNESP, and from January
2010 to December 2011 at HAC. The study was
approved by the Research Ethics Committee of FMB-
UNESP, under protocol no. 4385–2012.
Sociodemographic data and clinical information were
reviewed, including infectious comorbidities, history of
non-Hodgkin lymphoma (NHL), presence of B symp-
toms, nodal and/or extranodal involvement, central ner-
vous system (CNS) involvement, bone marrow
infiltration (MO), levels of lactic dehydrogenase (LDH),
Ann-Arbor staging, adopted therapeutic management,
clinical and evolutionary tracking and recurrences.
Morphological features
Hematoxylin and eosin (HE) slides of the 120 selected
biopsies were evaluated according to the morphological
criteria defined by the WHO, in its publication Classifi-
cation of Tumours of Haematopoietic and Lymphoid
Tissues, in 2008. The parameters adopted in this study
were monomorphic/polymorphic cytological pattern,
presence of “starry sky” pattern, diffuse growth, cytoplas-
mic eosinophilia, necrosis, mitotic activity, apoptosis,
nuclear characteristics (vesicular, lobed, nucleolus, chro-
matin pattern), endothelial proliferation, stromal scler-
osis and infiltration of adjacent soft tissues.
Immunophenotypic evaluation, fluorescence in situ
hybridization (FISH) and chromogenic in situ
hybridization (CISH)
For immunophenotypic and cytogenetic evaluation, a tis-
sue microarray platform (TMA) was constructed using
cores from selected areas of each biopsy of the 120
cases. The 1.0 mm diameter cores were duplicated, and
spaced every 0.2 mm [18].
Immunohistochemical analysis was performed using
the polymer detection system with staining with diami-
nobenzidine chromogen and counterstaining with
hematoxylin. The markers used were: CD20 (clone L26,
dilution 1: 250, Cell Marque), CD79a (clone JCB117,
Dako, ready to use), PAX5 (DAK-PAX5 clone, ready to
use, Dako), CD10 (clone 56C6, ready to use, Dako), Bcl6
(PGB6-P clone, ready to use, Dako), Bcl2 (clone 124,
ready to use, Dako), MUM1 (clone MUM1P, ready to
use, Dako), TDT (polyclonal, ready to use, Dako) and
Myc (clone EP121, ready to use, Biocare).
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The expressions CD20, CD79a, PAX5, CD10, MUM1
and TDT were evaluated for positivity or negativity. The
markers Myc, Bcl2 and Bcl6 were assessed for percent-
age of cellular expression. For Myc and BCL6, biopsies
were considered positive when the marker expression
was greater than 50% of tumor cells. For Bcl2, the criter-
ion of positivity used was 70% or more cells stained by
the marker. Evaluation of cell proliferation by Ki67
(Clone MIB-1, ready to use; Dako) was stratified into
less than 90%, and equal to or greater than 90%. The au-
thors classified the DLBCL cases with the Hans algo-
tithm, determining immunohistochemical patterns
compatible with the germinal center profile type (GCB)
and the non-germinal center profile type, also named B
cells activated (ABC).
Fluorescence in situ hybridization (FISH) analysis was
performed on the cores contained in the TMA block
using probes specific for translocation detection involv-
ing the loci of the MYC (Vysis LSI MYC-IGH dual color,
orange and green, break apart rearrangement probe;
Abbott Molecular Des Plaines, IL, USA), BCL2 (Dako,
BCL2 FISH DNA, red and green, probe split signal) and
BCL6 genes (Vysis LSI, BCL6, dual color, orange and
green, break apart probe rearrangement; Abbott
Molecular Des Plaines, IL, USA), following the man-
ufacturer’s instructions. The FISH results were ana-
lyzed by fluorescence microscopy (BX61; Olympus,
Center Valley, PA) with appropriate filters and the
images were captured with a Q-Color 5 Olympus
digital camera. A case was considered positive when
5.0% of the cells (at least 40 tumor cells were
counted) of a sample showed separate orange/red
and green signals [19].
Chromogenic in situ hybridization (CISH) for EBV
(Epstein Barr Virus) was performed on the cores of
TMA block using Vortex ZytoFast CISH probe, follow-
ing the manufacturer’s instructions. The CISH results
were analyzed by optical microscopy, and each core was
classified as positive or negative.
Statistical analysis
All analyzes were performed using SPSS, version 22.0.
The analysis was descriptive, followed by the Chi square
test and Fisher’s exact test to compare proportions. The
agreements between the immunohistochemical and
FISH tests for the MYC, BCL2 and BCL6 markers were
evaluated according to sensitivity, specificity, positive
and negative predictive values, accuracy and Kappa coef-
ficient, presented with their respective 95% confidence
intervals. The strength of the agreement determined by
the Kappa coefficient was analyzed as follows: poor
(<0.20), regular (0.21 to 0.40), moderate (0.41 to 0.60),
good (0.61 to 0, 80), very good (0.81 to 1.00). The signifi-
cance level (p-value) tested was 0.05.
Results
The 120 patients were submitted for clinical review,
morphological analysis, immunohistochemistry and
molecular evaluation. However, in 30 cases, flaws were
verified in molecular testing in one or more of the three
markers, related to issues of material fixation. FISH
analysis detected three cases of DHL. The three
groups defined by the cytogenetics investigation were
BL (n = 15), DHL (n = 3) and DLBCL (n = 72); the
sociodemographic, clinical, morphological, immuno-
histochemical and cytogenetic data are shown in
Table 1.
Clinical aspects
Patients with BL were predominantly male (60%),
with a median age of four years old (range: 2–48
years old), and included one with HIV. These patients
exhibited elevated LDH level (83.3%), stage III/IV in
clinical presentation (60%), extranodal masses (83.3%)
and lymphadenopathy (53.3%). Among patients with BL,
five patients (33.3%) died, approximately 1.2 months after
diagnosis (SD = 0.83).
Among patients with DLBCL, males predominated
(59.7%) and the median age was 56.5 years old (range:
25–69 years old), with 47.2% of patients over 60 years
old. Extranodal masses and enlarged lymph nodes
were present in 49.3 and 61.9% of cases, respectively.
Regarding treatment, 57 (79.2%) of the 72 cases diag-
nosed with DLBCL were submitted to the CHOP
(cyclophosphamide, doxorubicin hydrocloryde, vincris-
tine sulfate, prednisone) regimen, 11 were submitted
to a combination of CHOP with rituximab (R-CHOP)
and 14 required other therapeutic regimens. As for
clinical outcomes in the DLBCL group, 30 of the 72
cases (41.7%) resulted in death about 13 months after
diagnosis (SD = 13.99).
The three cases of DHL (Table 2) were two women
and a man, all over 60 years old, who presented no
comorbidities. One of this group was previously diag-
nosed as BL; the others, as DLBCL. None of them
received a B-CLU/DLBCL/LB diagnosis. Clinically, the
initial presentation in two patients was extranodal
mass. B symptoms and enlarged lymph nodes were
described in one patient. Neoplastic infiltration was
not detected in the bone marrow or CNS in all three
patients. None of these cases presented Ann-Arbor
stage III or IV. The clinical course of the DHL
patients was death in one, five and six months,
regardless of chemotherapy. One individual was pre-
scribed the R-CHOP regimen and another, the R-
HIPERCVAD regimen (cyclophosphamide, vincristine,
doxorubicin and dexamethasone). The patient that
died in less than 30 days did not start chemotherapy.
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Table 1 Sociodemographic. clinical. morphological. immunohistochemical and cytogenetic data of the diagnostic groups after FISH
Diagnostic Groups after FISH
BL (n = 15) DHL (n = 3) DLBCL (n = 72)
n % n % n %
Sociodemographic data
Woman 6 40 2 66.7 29 40.3
Man 9 60 1 33.3 43 59.7
Age over 60 years old 0 0 3 100 34 47.2
HIV 1 6.7 0 0 2 2.8
LNH history 0 0 0 0 2 2.8
Viral hepatitis 0 0 0 0 4 5.5
Morphology
Monomorphic 15 100 3 100 51 70.8
Polymorphic 0 0 0 0 21 29.1
“Starry sky” pattern 14 93.3 0 0 17 23.6
Diffuse growth 15 100 3 100 71 98.6
Necrosis 1 6.7 1 33.3 26 36.1
Mitotic activity 12 80 1 33.3 52 72.2
Apoptosis 14 93.3 3 100 57 79.1
Vesicular nuclear pattern 4 26.7 1 33.3 52 72.2
Evident nucleolus 5 33.3 0 0 64 88.8
Lobed nucleous 2 13.3 0 0 30 41.6
Dense chromatin 10 66.7 3 100 18 25
Loose chromatin 6 40 0 0 54 75
Endothelial proliferation 4 26.7 1 33.3 35 48.6
Cytoplasmic eosinophilia 7 46.7 3 100 43 59.7
Soft tissue infiltration 4 26.7 1 33.3 38 52.7
Stromal sclerosis 0 0 0 0 19 26.3
Immunohistochemistry
CD20 15 100 3 100 68/70 97.1
CD79a 14 93.3 2 66.7 66/70 94.3
PAX5 11 73.3 1 33.3 49/70 70
CD10 15 100 3 100 31/71 43.6
Bcl6 7 46.7 2 100 22/70 31.4
Bcl2 0 0 2 100 29/71 40.8
MUM1 0 0 0 0 37/71 52.1
TDT 0 0 0 0 0 0
Myc 5 33.3 0 0 11/70 15.7
Ki-67 > 90% 3 20 2 66.7 9/70 12.8
Cytogenetic
MYC 15 100 3 100 3 4.2
BCL2 0 0 2 66.7 11 15.3
BCL6 0 0 1 33.3 9 12.5
Prognostic markers
High levels of LDH 5/6 83.3 2 66.7 37/47 78.7
Staging III/IV 9 60 0 0 29/71 40.8
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Morphological aspects
The monomorphic and diffuse pattern with a “starry
sky” appearance was the main aspects of the BL group,
as expected according to the literature. Among the
DLBCL patients, the morphological pattern of diffuse
growth was frequent (98.6%), with a “starry sky” pattern
in 23.6% of the cases studied.
In the DHL group, the typical morphology in our
study was diffuse monomorphic pattern, eosinophilic
cytoplasm and apoptotic elements. The “starry sky” pat-
tern, sclerosis or nuclear lobulation were not observed
in this group.
Immunohistochemical aspects
The B immunophenotype was confirmed in all cases of
BL. Positivity for CD10 (100%) and Bcl6 (46.7%) were
also observed.
In the DLBCL group, among 70 patients, 34 were
GCB type and 36 were ABC type. For the ABC type
patients, in the immunohistochemistry analysis, one was
BCL6 positive, 20 were Bcl2 positive and two patients
are positive for Myc and Bcl2.
The three DHL had a B immunophenotype. MUM-
1, TDT and MYC were negative in all three biopsies.
One case was positive for both BCL6 and BCL2. Cell
proliferation, measured by Ki-67, was higher than
90% in two cases.
Molecular aspects
Molecular cytogenetic by FISH showed that all 15
patients diagnosed as BL presented translocation
involving the MYC gene. In this group, one of five
patients over 18 years old tested positive for EBV on
the CISH test.
In the DLBCL group, positivity for MYC, BCL2 and
BCL6 was determined in three (4.2%), nine (12.5%) and
11 cases (15.3%), respectively. In these patients, a statis-
tically significant association (p = 0.011) between the
Table 1 Sociodemographic. clinical. morphological. immunohistochemical and cytogenetic data of the diagnostic groups after FISH
(Continued)
Bone marrow infiltration 2 13.3 0 0 12/71 16.9
CNS infiltration 1 6.7 0 0 4/71 5.6
B symptoms 9 60 1 33.3 31/71 43.6
Extranodal involvement 8 53.3 2 66.7 35/71 49.3
Nodal involvement 8 53.3 1 33.3 44/71 61.9
Therapeutic data
Chemotherapy 11 73.3 2 66.7 65/71 91.5
Chemotherapy and radiotherapy 1 6.6 0 0 17 26.6
Bone marrow transplant 0 0 0 0 1 1.4
Death 5 33.3 3 100 30/66 45.4
Recurrence 0 0 0 0 2/59 3.4
Table 2 Clinical, immunophenotypic and cytogenetic of the
three patients with double-hit lymphomas (DHL)
Patient 1 Patient 2 Patient 3
Age 65 year old 72 year old 64 year old
Gender Woman man woman
Previous diagnosis BL DLBCL DLBCL
Immunohistochemistry
CD20 positive positive positive
CD79a negative positive positive
PAX5 positive negative positive
CD10 positive positive positive
Bcl2 negative positive positive
Bcl6 positive negative positive
Myc negative negative negative
MUM1 negative negative negative
TDT negative negative negative
Ki-67 >90% >90% <90%
Cytogenetic
MYC positive positive positive
BCL2 negative positive positive
BCL6 positive negative negative
Clinical data
Staging IA IA IB
Levels of LDH High ND* ND*
Bone marrow infiltration absent absent absent
CNS infiltration absent absent absent
Extra nodal involvement absent presence presence
Nodal involvement presence absent absent
B symptoms absent absent presence
Treatment HIPER-CVAD Not treated R-CHOP
Death Yes yes Yes
Interval to death 5 months 1 month 6 months
*ND=not avaible
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positivity for MYC translocation and the “starry sky”
morphological pattern was noted. Concerning EBV
status, the CISH revealed ten positive cases in the
DLBCL group.
One of the three DHL patients presented translocation
of the MYC gene simultaneously with the BCL6 gene
translocation (Patient 1; Fig. 1) and the others presented
translocation involving the MYC gene simultaneously
with the BCL2 gene (Patients 2 and 3). In this series,
there were no cases of triple-hit lymphoma. None of the
three patients tested positive for the EBV infection on
CISH test.
Correspondence between the cytogenetic findings and
immunohistochemical profile for the entire set of cases
is shown in Table 3. Immunohistochemical positivity for
Myc was verified in 19 cases, eight (42.1%) of which
were also positive in the cytogenetic analysis (p = 0.036).
For this marker, the immunohistochemical technique
showed high specificity (85%) and low sensitivity (38%),
with regular agreement at identifying the respective
translocation (Kappa = 0.23 [0.0,0.49]). Regarding Bcl2,
the most interesting aspect is the high NPV, which is
95% (p = 0.001), with regular agreement (Kappa = 0.35
[0.13;0.56]). Four (12.5%) of the 32 cases positive for
Bcl6 by immunohistochemistry showed positivity in
FISH (p = 0.724), indicating poor agreement between the
two methods for this marker (Kappa = 0.04 [0.00;0.30]).
The findings related to BCL6 gene were not statistically
significant.
Evaluation of these associations considering only
patients with DLBCL are shown in Table 4. In this
group, nine cases (31%, p = 0.005) showed immunohisto-
chemical and cytogenetic positivity for BCL2, with a
regular agreement (Kappa = 0.29 [0.04; 0.54]). Parame-
ters, such as a cell proliferation rate above 90%, an ABC
type, and immunohistochemical positivity for Myc, were
not associated with the detection of MYC translocation
by FISH.
Discussion
DHL are rare, aggressive neoplasms that account for less
than 10% of B-cell lymphomas and about 4% of high-
grade lymphomas [4, 12]. This first Brazilian study found
three cases of DHL, two with translocations involving
MYC and BCL2, and one with translocations involving
MYC and BCL6. The combination that is most often
reported is the double translocation involving the MYC
gene and the BCL2 gene (62%) [4, 20].
The most important clinical and prognostic factors of
DHL patients are the advanced stage at diagnosis, the
presence of extranodal masses, the bone marrow or
CNS infiltration and the age of over 60 years old [4, 10,
12, 16, 21]. The three patients identified in this study
were elderly; however, they did not present high Ann-
Arbour stages or bone marrow/CNS infiltration, though
two of the patients exhibited extranodal masses.
Survival is lower in patients with DHL. In this study,
all three patients with DHL died, an average of 4 months
Fig. 1 Morphological, cytogenetic and immunohistochemical aspects of patient 1. Key: Images a, b and c correspond to FISH: there is positivity
for MYC (a) and BCL6 (c), in this case, the signals are indicated with arrows, and there is negativity for BCL2 (b). Images d (400x) and e (400x)
exhibit the negativity for Bcl2 (below 70% of marked cells) and Myc in immunohistochemistry (below 50% of marked cells). In image f (400x),
there is BCL6 positivity (above 50% of marked cells). Image g (H&E, 400x): the diffuse pattern in morphology. Positivity for CD20 confirms
immunophenotype B and is shown in image h (400x). Image i (400x) refers to cell proliferation rate above 90%
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after diagnosis. According to the literature [16], the
overall median survival rate is 8.2 months in this
group of patients versus 56.8 months in patients with
other high-grade lymphomas. Snurdel et al. (2010)
[10] reported 70% of deaths within eight months in
patients with DHL. The aggressiveness of DHL is pos-
sibly explained by the synergistic action of MYC and
BCL2: proliferative activity with inhibition of apop-
tosis in the context of a complex karyotype [4, 20,
22, 23].
In this study, the best agreements between immuno-
histochemical and FISH results occurred with respect to
the MYC gene and, mainly, the BCL2 gene, with high
NPV. Evaluations of the MYC gene and the BCL2 gene
shows good results, however, there is a fair agreement by
Kappa coefficient, indicating the need for caution in
assessing the markers with the immunohistochemical
method.
Immunohistochemical evaluation of Myc, Bcl2 and
Bcl6 is a problem discussed by several hematopathol-
ogy groups [12, 22–24]. The cutoff for determining
positivity for MYC varies between 30 and 50% in the
literature, while for Bcl2, the variation is between 30
and 70% [22, 23, 27].
Perry et al. [24] studied the immunohistochemical ex-
pression of Myc and Bcl2 of 106 patients diagnosed with
DLBCL, correlating their data with prognosis. Positivity
for these markers, especially when both were positive,
was related to worse prognosis, increasing the chances
of death nine-fold. However, Perry et al. (2014) did not
correlate their results with cytogenetic data [24].
Green et al. [25] studied the immunohistochemical
and cytogenetic profiles of 193 patients diagnosed with
DLBCL, of which 6% were DHL identified by FISH, and
showed poor prognosis. Regarding immunohistochemis-
try, 29% of patients were positive for Myc and Bcl2, and
54% of these patients had translocations involving one of
these genes. These patients, regardless of the cytogenetic
test results, showed worse survival rates compared with
other patients [25].
Yan et al. [26] evaluated 336 patients with DLBCL by
immunohistochemistry and FISH, and found a high spe-
cificity (approximately 90%) of positivity for Myc and
Bcl2 in the immunohistochemistry in relation to FISH
Table 3 Immunohistochemistry (IHC) for Myc, Bcl2 and Bcl6 and cytogenetic (FISH) for MYC, BCL2 and BCL6, considering the total
number of valid samples: sensitivity (S), specificity (E), positive predictive value (PPV) and negative predictive value (NPV), accuracy
(A) and Kappa coefficient, with respective ranges of 95% confidence
n FISH+ p* S E PPV NPV A Kappa
MYC (n = 92)
IHC negative 73 13 (18.0%) 0.036 0.38 0.85 0.42 0.82 0.74 [0.65;0.83] 0.23 [0.0;0.49]
IHC positive 19 8 (42.1%)
BCL2 (n = 101)
IHC negative 64 3 (4.6%) 0.001 0.81 0.71 0.35 0.95 0.73 [0.64;0.81] 0.35 [0.13;0.56]
IHC positive 37 13 (35.1%)
BCL6 (n = 98)
IHC negative 66 6 (9.0%) 0.724 0.40 0.68 0.12 0.90 0.65 [0.56;0.75] 0.04 [0.0;0.30]
IHC positive 32 4 (12.5%)
*p < 0.05
Table 4 Immunohistochemistry (IHC) for Myc, Bcl2 and Bcl6 and cytogenetic (FISH) for MYC, BCL2 and BCL6, considering the group
of DLBCL: sensitivity (S), specificity (E), positive predictive value (PPV) and negative predictive value (NPV), accuracy (A) and Kappa
coefficient, with respective ranges of 95% confidence
n FISH+ p* S E PPV NPV A Kappa
MYC (n = 70)
IHC negative 59 1 (1.7%) 0.062 0.67 0.87 0.18 0.98 0.86 [0.78;0.94] 0.23 [0.0;0.67]
IHC positive 11 2 (18.1%)
BCL2 (n = 71)
IHC negative 42 2 (4.7%) 0.005 0.81 0.66 0.31 0.95 0.69 [0.58;0.79] 0.29 [0.04;0.54]
IHC positive 29 9 (31%)
BCL6 (n = 70)
IHC negative 48 6 (12.5%) 1.000 0.33 0.69 0.13 0.87 0.64 [0.53;0.76] 0.01 [0.0;0.32]
IHC positive 22 3 (13.6%)
*p < 0.05
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positivity for MYC and BCL2 translocations, favoring its
potential use for stratification in cases of DLBCL with
aggressive behavior [26]. Kawamoto et al. [15] studied only
DLBCL patients, by FISH and immunohistochemistry.
They found that MYC translocation and Bcl2 immunohis-
tochemical expression were independent prognostic fac-
tors and must be investigated at the initial diagnosis [15].
Kalaw et al. [28] studied the cell proliferation rate,
measured by the percentage of staining for Ki67, as a
potential selection parameter of patients for cytogenetic
tests. The cutoff values used were 75% or 90% and both
were not associated with detection of MYC transloca-
tions, as was seen in this study.
Mahmound et al. (2015) [27] studied the agreement in
the evaluation of Myc expression by immunohistochemis-
try and noted great heterogeneity in the results, reflecting
the subjective interference and the lack of a clear standard
regarding the interpretation of this marker [27].
In this study, the “starry sky” morphological pattern, in
the DLBCL context, positive immunohistochemistry for
Myc in over 50% of cells, and positive immunohisto-
chemistry for Bcl2 above 70% are indicated as potential
selector parameters for patients eligible for cytogenetic
study. However, further studies with larger case samples
are required, for more detailed analysis of these associa-
tions, in special morphological pattern studies because it
is a conventional and accessible method of evaluation in
the pathology routine.
Swerdlow (2014) [23] emphasizes the importance of
identifying cases of aggressive large B cell lymphomas,
mainly due to the absence of a specific therapeutic
protocol [23]. In this context, there is great interest in
studies of agreement between immunohistochemical and
cytogenetic results, mainly in relation to selector
elements for molecular screening. In fact, difficulties
related to the standardization of defining criteria of
positivity for Myc and Bcl2 in immunohistochemical
reactions has been reported.
Conclusions
This study presents the first Brazilian series of patients
with double-hit lymphoma identified by cytogenetic study
performed by FISH on 120 cases of high-grade lymph-
omas. For this study, high grade B-cell lymphomas, par-
ticularly when there is a “starry sky” pattern, must be
submitted to immunohistochemistry for, at least, Myc
andBcl2. When Myc and/or Bcl2 are positive, if it is
possible, the investigation must continue with FISH
test for MYC, BCL2 and BCL6. These cases are high
grade lymphomas and the molecular markers must be
reported. In the situation that molecular approach is
not possible, the immunohistochemistry results must
be reported too, because they may represent a prog-
nostic factor.
Abbreviation
ABC: B cell activated or non-germinal centre; B-CLU/DLBCL/LB: B-cell
lymphoma unclassifiable, with features intermediate between diffuse large
B-cell lymphoma and Burkitt lymphoma; BL: Burkitt lymphoma; CISH for
EBV: Chromogenic in situ hybridization (CISH) for EBV (Epstein Barr Virus);
CNS: Central nervous system; DHL: Double-hit lymphomas; DLBCL: Diffuse
large B-cell lymphoma; Fish: Fluorescence in situ hybridization; GCB:
B germinal centre; HE: Hematoxylin and eosin; LDH: Lactic dehydrogenase;
MO: Bone marrow infiltration; NHL: Non-Hodgkin lymphoma; THL: Triple-hit
lymphomas; TMA: Tissue microarray platform
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